ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Mar 28, 2024
Micron Issues Strong Outlook, Points to Multi-Year Opportunity in AI
Image Source: Micron. Micron operates in the ultra-cyclical semiconductor industry, and while the next few quarters may be robust, we’re cautious on the sustainability of the momentum and pricing health beyond the next few quarters, despite management’s optimism in fiscal 2025. Free cash flow has also been negative during the first six months of its fiscal year, and its net debt position precludes it from being a net-cash-rich, free-cash-flow generating powerhouse like so many other companies in the technology space. All things considered, we liked Micron’s quarterly report and outlook, but it’s not enough for us to pull the trigger on the idea for the Best Ideas Newsletter portfolio.
Mar 27, 2024
Boeing Shakes Up Executive Team
Image Source: Kanesue. We like the shake-up in the executive suite at Boeing, and while there is much work to do to get Boeing back on track to improve relations with the public regarding the safety of their planes following a number of incidents the past few years, we're optimistic the changes will be a means to that end. Boeing continues to benefit from its oligopolistic position in the aircraft making industry, and its backlog of unfulfilled deliveries remains robust. We're not changing our fair value estimate of Boeing as a result of the management shakeup, but we don't have any plans of adding Boeing to any newsletter portfolio at this time either.
Mar 25, 2024
Fedex Bolstered By Cost Savings from Its DRIVE Program
Image: FedEx continues to extract cost savings from its DRIVE initiatives. FedEx is doing a lot of things right as it drives cost savings from its DRIVE program in the face of a challenging revenue environment. Shares of FedEx bounced nicely following the release of its fiscal third quarter report, and while they aren’t trading at bargain basement prices on the basis of our fair value estimate, we think shares could have upside to north of $300 based on the high end of our fair value estimate range. Shares yield ~1.8% at the time of this writing.
Mar 24, 2024
Ameresco’s Shares Under Pressure Despite Record Backlog and Asset Pipeline Metrics
Image Source: Ameresco’s backlog of opportunities remains robust. We like the trajectory of Ameresco’s backlog, its order momentum as well as commentary that “proposal activity (remains) at an all-time high.” The company’s track record and technical know-how suggest to us that win rates will likely continue to be healthy. That said, we continue to monitor Ameresco’s debt position and adjusted operating cash flow trends closely, and while the firm remains an idea in the ESG Newsletter portfolio, we’re viewing it as a source of cash should another ESG idea present a better risk-reward opportunity.
Mar 22, 2024
Nike’s Revenue to Face Pressure During First Half of Fiscal 2025
Image: Nike’s shares have faced considerable pressure from the beginning of 2022, and its outlook for the first half of fiscal 2025 wasn’t great. We’re huge fans of Nike’s consecutive dividend growth track record, but uncertainty regarding the future pace of sales growth in China, growing competition from the likes of Lululemon and Vuori, and macro-driven weakness expected in the first half of fiscal 2025 leave us on the sidelines for now. Shares yield ~1.5% at the time of this writing.
Mar 22, 2024
Dividend Increases/Decreases for the Week of March 22
Let's take a look at firms raising/lowering their dividends this week.
Mar 21, 2024
Pfizer 6% Dividend Yield Speaks of Considerable Risk, Free Cash Flow Coming Up Short
Image: Pfizer’s shares have been under considerable pressure the past few years. Though we are positive on Pfizer’s turnaround, its Dividend Cushion ratio of 0.3 is not to be taken lightly (any ratio below 1 indicates heightened risk of a dividend cut). Income-oriented investors seeking a turnaround story may be interested in Pfizer, but we’re staying on the sidelines. We’ll continue to monitor developments at the pharma giant, especially as patents on several of its major drugs approach expiration. Shares yield ~6% at the time of this writing.
Mar 20, 2024
Phillips 66 Hovering Near All-Time Highs, Shares Yield ~2.7%
Image: Phillips 66 continues to be very shareholder friendly returning cash in the form of share repurchases and dividends. Though crack spreads can be quite volatile at times, there’s a lot to like about Phillips 66. The company is targeting 2025 mid-cycle adjusted EBITDA of $14 billion, up from $10 billion in 2022. Cost savings should remain ongoing, with its target calling for a total of $1.4 billion in savings, implying the company has $200 million more in savings to go. We like its investment-grade (A3/BBB+) balance sheet and target for 2025 mid-cycle adjusted operating cash flow of $10+ billion, up from $7 billion in 2022, with expectations that it will return more than half of operating cash flow to shareholders. Phillips 66 is a quality income idea for investors seeking exposure to the energy space.
Mar 19, 2024
Hasbro Is Down But Not Out, Shares Yield ~5.3%
Image: Hasbro’s shares have faced considerable pressure during the past few years. Hasbro's recently reported fourth-quarter results weren't great and showed revenue declining 23% as it experienced material weakness in its Consumer Products segment (-25%) and Entertainment division (-49%) in the quarter. On an adjusted basis, backing out large impairment charges, the firm’s operating loss came in at $50 million in the quarter, while it recorded adjusted net earnings of $0.38 per share. Hasbro continues to navigate a difficult demand environment for physical toys, but the company’s free cash flow remains robust and was in excess of cash dividends paid during 2023. Shares yield ~5.3% at the time of this writing.
Mar 15, 2024
Dividend Increases/Decreases for the Week of March 15
Let's take a look at firms raising/lowering their dividends this week.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.